Insight

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

Collage photo of Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer

Nov 10, 2024, 16:37

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

A recent paper by Guilherme Nader-Marta, Clinical Fellow at Dana-Farber Cancer Institute, was mentioned by Dana-Farber’s Breast Oncology Center on X:

“Check out this new editorial in ESMO Open on the incorporation of immunotherapy in the management of early-stage estrogen receptor-positive Breast Cancer.”

“Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer”

Authors: Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer.

Posts featuring Dana-Farber’s Breast Oncology Center

Adrienne Waks cancer Dana-Farber’s Breast Oncology Center ER+ breast cancer Erica Mayer ESMO Open Guilherme Nader Marta OncoDaily Oncology Sara Tolaney

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage